Clinical Trials on Spondylarthritis in Czechia

Total 105 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Merck Sharp & Dohme LLC

Completed

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

Spondyloarthritis

Czechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Ukraine, Taiwan, Poland, Korea, Republic of, Russian Federation, Czechia
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis (BE MOBILE 1)

Nonradiographic Axial Spondyloarthritis

United States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of Adalimumab in Patients With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Netherlands, Spain, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Non-radiographic Axial Spondyloarthritis

Belgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
UCB BIOSCIENCES GmbH

Completed

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

Axial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpA

United States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
UCB Biopharma SRL

Completed

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (C-VIEW)

Axial Spondyloarthritis (axSpA) | Anterior Uveitis (AU)

Czechia, Germany, Netherlands, Poland, Spain
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)

Axial Spondyloarthritis

United States, Puerto Rico, Russian Federation, Mexico, Poland, Argentina, Austria, Brazil, Canada, Czechia, Finland, Germany, Japan, Korea, Republic of, Netherlands, Romania
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)

Non-radiographic Spondyloarthritis

United States, Spain, Belgium, Hungary, Turkey, Netherlands, Austria, Israel, Sweden, Switzerland, Germany, Korea, Republic of, Australia, Russian Federation, Italy, Portugal, United Kingdom, Bulgaria, France, Czechia, Poland, Japan, Mexi... and more
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia
UCB Biopharma SRL

Active, not recruiting

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (BE MOVING)

Ankylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpa

United States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
Eli Lilly and Company

Completed

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Puerto Rico, Korea, Republic of, Netherlands, Taiwan, Canada, Israel, Spain, Japan, Brazil, Argentina, Hungary, Poland, Czechia, France, Russian Federation, Germany, Mexico, United Kingdom, Romania, Italy, Finland, Au...
Galapagos NV

Active, not recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

Axial Spondyloarthritis

Belgium, Korea, Republic of, Greece, Taiwan, France, Romania, Germany, Netherlands, Italy, Philippines, United Kingdom, Hungary, Estonia, South Africa, Bulgaria, Spain, Croatia, Czechia, Poland, Lithuania
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)

Spondyloarthritis

Taiwan, United States, Korea, Republic of, Germany, Czechia, Japan, Netherlands
Amgen

Completed

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis (POSTURE)

Ankylosing Spondyloarthritis

United States, Russian Federation, Spain, Netherlands, Germany, France, Australia, Czechia, Hungary, Poland, Slovakia, Estonia, Canada, United Kingdom, Romania, Austria, Bulgaria, Sweden
Novartis Pharmaceuticals

Completed

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (SKIPPAIN)

Spondyloarthritis

Belgium, Croatia, Switzerland, Spain, Greece, United Kingdom, Bulgaria, Latvia, Lithuania, Estonia, Italy, Poland, Czechia, Sweden, Russian Federation, Ireland, Finland
Galapagos NV
Gilead Sciences

Completed

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis (MANTA-RAy)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Non-Radiographical Axial Spondyloarthritis

Bulgaria, Ukraine, Poland, Estonia, Czechia, Georgia, Latvia, Spain
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

United States, Czechia, Germany, Greece, Moldova, Republic of, Netherlands, Poland, Russian Federation
AbbVie

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

Spondyloarthritis

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukr... and more
UCB Biopharma SRL

Completed

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis (BE AGILE 2)

Ankylosing Spondylitis

United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
Celgene

Terminated

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis (AS SpA axSpA)

Spondylitis, Ankylosing

United States, China, Czechia, Germany, Poland, Romania, Spain, Turkey
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis (BE AGILE)

Ankylosing Spondylitis

United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis (BE MOBILE 2)

Ankylosing Spondylitis

United States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (SURPASS)

Ankylosing Spondylitis

Taiwan, Netherlands, United Kingdom, Germany, Korea, Republic of, Israel, United States, Belgium, Greece, Philippines, Russian Federation, Spain, Turkey, Portugal, Mexico, Peru, Denmark, France, Czechia, Australia, Canada, Poland, J... and more
Sanofi
Regeneron Pharmaceuticals

Terminated

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis (SUSTAIN)

Ankylosing Spondylitis

United States, France, Canada, Poland, Netherlands, Spain, Belgium, Hungary, Lithuania, Austria, Czechia, Australia
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (TORTUGA)

Ankylosing Spondylitis

Belgium, Bulgaria, Czechia, Estonia, Poland, Spain, Ukraine
Faculty Hospital Kralovske Vinohrady

Completed

The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic

Infections | Multiple Sclerosis | Autoimmune Diseases | Diabetes Mellitus, Type 1 | Rheumatoid Arthritis | Vaccine Reaction | Inflammatory Bowel Diseases | Psoriasis | Crohn Disease | Ulcerative Colitis | Down Syndrome | Atopic Dermatitis | Vitiligo | Alopecia Areata | COVID-19 Pandemic | Ankylosing Spondylitis | Lupus Erythematosus and other conditions

Czechia
ACELYRIN Inc.

Completed

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Hungary, Germany, Belgium, Czechia, Austria, Spain
Novartis Pharmaceuticals

Completed

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)

Spondylitis, Ankylosing

Germany, Spain, United Kingdom, United States, Belgium, Greece, Portugal, Russian Federation, Czechia, Mexico
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Spain, Bulgaria, Poland, Czechia, Estonia, Germany, Hungary
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis (BE ACTIVE 2)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4)

Arthritis, Psoriatic

United States, Italy, Germany, Australia, Belgium, Poland, Bulgaria, Russian Federation, Czechia, Canada, France, Sweden, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Psoriatic Arthritis

United States, Bulgaria, Czechia, Germany, Hungary, Poland, Spain
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Pfizer

Completed

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA (RE-EMBARK)

Spondylitis, Ankylosing

United States, Sweden, Taiwan, Colombia, Hungary, Belgium, Australia, Finland, Netherlands, Spain, Czechia, Poland, France, Germany
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Takeda
Nimbus Lakshmi, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Poland

Clinical Trials on Spondylarthritis in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations